A Phase I Clinical Study of BBI608 Administered with Paclitaxel in Patients with Previously treated Unresectable/Recurrent Gastric Cancer
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2017
Price : $35 *
At a glance
- Drugs Napabucasin (Primary) ; Paclitaxel
- Indications Gastric cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sumitomo Dainippon Pharma
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Status changed from not yet recruiting to completed, as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 01 Jun 2015 Results from this study will be presented at the 2015 annual meeting of the American Society of Clinical Oncology, according to a Boston Biomedical media release.